RE: We are in…15 Jun 2022 22:34
If this shows promise then all eyes could be on this drug with no clear drug related treatments other than chemo. It could get the entire world interested in VAL. At the current market cap this is cheap. Successful trials for phase 2b for 201 and that alone could be worth £2 plus. Looking at a £ 5 market cap for Val in the 2-3 years if one of the preclinical does well as well.
Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted HER2 drugs work. Because hormone therapy and anti-HER2 drugs are not choices for women with triple-negative breast cancer, chemotherapy is often used.
If the cancer has not spread to distant sites, surgery is an option. Chemotherapy might be given first to shrink a large tumor, followed by surgery. Chemotherapy is often recommended after surgery to reduce the chances of the cancer coming back. Radiation might also be an option depending on certain features of the tumor and the type of surgery you had.
In cases where the cancer has spread to other parts of the body (stage IV), platinum chemotherapy, targeted drugs like a PARP inhibitor, or antibody-drug conjugate, or immunotherapy with chemotherapy might be considered.